调脾护心方治疗心脾两虚型心房颤动的临床观察

Clinical Observation on Regulating the Spleen and Protecting the Heart Formula for the Treatment of Atrial Fibrillation with Deficiency of Both the Heart and the Spleen

摘要: 目的：探讨调脾护心方治疗心脾两虚型心房颤动患者的临床疗效。方法：选择60例心脾两虚型房颤患者，随机分为两组，观察组30例，对照组30例，均给予控制心室率西药(琥珀酸美托洛尔片)及抗凝西药(利伐沙班片)治疗；观察组在此基础上加用调脾护心方治疗，两组疗程均为12周，评估两组24 h平均心室率、左房内径(LAD)、左心室射血分数(LVEF)、心房颤动症状疗效和中医证候积分疗效等。结果：治疗后，两组24 h平均心室率均降低(P < 0.01)。观察组较对照组下降更明显(P < 0.01)。LAD比较治疗前后均无统计学意义(P > 0.05)；治疗后两组的LVEF值均上升(P < 0.05)。治疗后中医证候积分均下降(P < 0.05)。证候总有效率观察组的(90%)优于对照组的(56.7%) (P < 0.05)。房颤症状有效率观察组的90%明显优于对照组的(66.7%) (P < 0.05)。结论：调脾护心方治疗心脾两虚型心房颤动的疗效良好，可改善患者整体健康状况。

Abstract: Objective: To evaluate the clinical efficacy of Tiaopi Huxin Decoction in treating patients with heart-spleen deficiency type atrial fibrillation (AF). Methods: A total of 60 patients diagnosed with heart-spleen deficiency type AF were randomly assigned to two groups: the observation group (30 patients) and the control group (30 patients). Both groups received standard treatment with rate control medication (Metoprolol Succinate Tablets) and anticoagulant therapy (Rivaroxaban Tablets). In addition to these treatments, the observation group was given Tiaopi Huxin Decoction. The treatment duration for both groups was 12 weeks. Key outcomes, including 24-hour average ventricular rate, left atrial diameter (LAD), left ventricular ejection fraction (LVEF), AF symptom improvement, and Traditional Chinese Medicine (TCM) syndrome scores, were assessed for both groups. Results: Post-treatment, the 24-hour average ventricular rate decreased in both groups (P < 0.01), with the observation group showing a significantly greater reduction compared to the control group (P < 0.01). There was no significant difference in LAD before and after treatment in either group (P > 0.05). LVEF improved in both groups after treatment (P < 0.05). TCM syndrome scores significantly decreased in both groups, with the observation group showing a more pronounced improvement (P < 0.05). The total effective rate for syndrome treatment in the observation group (90%) was significantly higher than that in the control group (56.7%) (P < 0.05). The AF symptom efficacy rate was also notably higher in the observation group (90%) compared to the control group (66.7%) (P < 0.05). Conclusion: The Spleen-Regulating and Heart-Protecting Formula has good efficacy in treating atrial fibrillation with heart-spleen deficiency, improving patients’ overall health condition.